Drugs / Measles and Rubella Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06879327 Background | May 2025 → Oct 2027 expected | Plasmodium falciparum malaria | PATH | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles and Rubella Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879327 ↗ |
| Modality | Vaccine | “Measles and Rubella Vaccine” NCT06879327 ↗ |
| Route | Subcutaneous | “Administered by subcutaneous injection.” NCT06879327 ↗ |